Sorafenib

Generic Name: Sorafenib

Brand Names: Nexavar, Sorafenib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₆ClF_₃N_₄O_₃

CAS Number: 284461-73-0

Unique Ingredient Identifier: 9ZOQ3TZI87

Background: Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...

Indication: Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.

In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.

Associated Conditions: Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)

Associated Therapies: -

Clinical Trials

Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Lung Cancer

Interventions: Drug: Sorafenib
Procedure: Radiation Therapy

First Posted Date: 2007-10-12

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00543335

Locations: 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States

Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
AML
Myelodysplastic Disorders

Interventions: Drug: Idarubicin
Drug: Sorafenib
Drug: Ara-C

First Posted Date: 2007-10-12

Last Posted Date: 2018-08-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 78

Registration Number: NCT00542971

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma

Phase 1

Conditions: Soft Tissue Sarcoma

First Posted Date: 2007-10-10

Last Posted Date: 2008-05-12

Lead Sponsor: Grupo Espanol de Investigacion en Sarcomas

Target Recruit Count: 24

Registration Number: NCT00541840

Locations: 🇪🇸
Grupo Geis, Madrid, Spain

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Sorafenib

First Posted Date: 2007-09-28

Last Posted Date: 2013-02-27

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 13

Registration Number: NCT00536575

Locations: 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Sorafenib in Resected Non-small Cell Lung Carcinoma

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Sorafenib

First Posted Date: 2007-09-19

Last Posted Date: 2009-07-28

Lead Sponsor: Johannes Gutenberg University Mainz

Target Recruit Count: 134

Registration Number: NCT00532025

Locations: 🇩🇪
SIRN investigational trial site, Rotenburg (Wuemme), Germany
🇩🇪
SIRN investigational trial site Johannes Gutenberg Universität, Mainz, Germany
🇩🇪
SIRN investigational trial site Katholisches Klinikum, Mainz, Germany

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Sorafenib
Drug: Topotecan

First Posted Date: 2007-09-10

Last Posted Date: 2016-03-03

Lead Sponsor: Daniela Matei, MD

Target Recruit Count: 30

Registration Number: NCT00526799

Locations: 🇺🇸
Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States
🇺🇸
Schwartz Gynecologic Oncology, PLLC, Brightwaters, New York, United States
🇺🇸
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States

and more 5 locations

Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: sorafenib

First Posted Date: 2007-09-05

Last Posted Date: 2015-01-26

Lead Sponsor: Suleiman Massarweh

Target Recruit Count: 11

Registration Number: NCT00525161

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer

Phase 1

Completed

Conditions: Cancer of the Cervix

Interventions: Drug: Sorafenib
Drug: Cisplatin
Procedure: Radiation

First Posted Date: 2007-08-01

Last Posted Date: 2015-07-27

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 13

Registration Number: NCT00510250

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Sorafenib in Myelodysplastic Syndrome

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic

Interventions: Drug: Sorafenib

First Posted Date: 2007-08-01

Last Posted Date: 2016-04-19

Lead Sponsor: Duke University

Target Recruit Count: 19

Registration Number: NCT00510289

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Phase 1 Study With Sorafenib and Sirolimus

Phase 1

Completed

Conditions: Advanced Solid Tumor
Refractory to Standard Therapies

First Posted Date: 2007-07-31

Last Posted Date: 2009-09-18

Lead Sponsor: Radboud University Medical Center

Registration Number: NCT00509613

Locations: 🇳🇱
UMC St Radboud, Nijmegen, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy